Astellas's Vesicare to be launched soon

Published: 2007-11-01 06:58:00

Updated: 2007-11-01 06:58:00

Astellas Pharma Korea said on October 29 that Vesicare (solifenacin succinate) for the treatment of the overactive bladder (OAB) with the indication of urinary frequency, urgency and urge incontinence associated with OAB will be launched in Korea, following its insurance price listing with the in...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK